ClinicalTrials.gg
Not yet recruitingNCT07947966Updated Nov 19, 2026

Safety and Drug Concentrations of REGN20566 in Adults With Overweight or Obesity

A Phase 1 interventional study of REGN20566 and Placebo in Overweight and Obesity, sponsored by Regeneron Pharmaceuticals. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies in Obesity by Regeneron Pharmaceuticals — 5 open to participants now, 8 under way, 1 of them phase 3. Obesity · Regeneron Pharmaceuticals.

Planned enrollment
5th of 10
304 · median 302
Started
2026
with 6 others
Phase 1
3 of 10
2 open now
Registered
10th of 10
by date

Among the 10 studies in Obesity by Regeneron Pharmaceuticals, this one is the 5th largest by planned enrollment, is one of 7 that started in 2026, is one of 3 in phase 1, and was the 10th registered.

Obesity

11,560 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 10 studies in Obesity by Regeneron Pharmaceuticals are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Obesity by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

This study will test a Regeneron drug called REGN20566 ("study drug") to see how safe it is and how participants with overweight or obesity respond to it.

The study will be split into two parts, Part A and Part B.

The study is looking at:

  • What side effects REGN20566 might cause
  • How much REGN20566 is in the blood at different times
  • If the body reacts to REGN20566 in a way that may cause REGN20566 to not work as well
Read the detailed description

Total planned duration of trial participation for each participant (excluding screening period):

  • Part A: approximately 16 weeks
  • Part B: approximately 27 weeks
03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

Keywords

  • Adiposity
  • Anti-Obesity Medication
  • BMI
  • Body Mass Index
  • Glucose Homeostasis
  • Glucose Tolerance
  • Healthy volunteers with obesity
  • Weight Reduction
04

In context

Obesity Reclassified

11,560 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

This study's planned enrollment of 304 is above the median of 67 across 9,036 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 413 studies on the registry; 91 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 80 (63%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Has a 27-40 kg/m2, inclusive, at screening visit or prior to randomization
  2. Healthy volunteers with obesity

Key Exclusion Criteria:

  1. A self-reported change of body weight >5 kg within 90 days of screening visit
  2. History of type 1 or 2 diabetes, or bariatric surgery
  3. (HbA1c) ≥6.5% at the screening visit
  4. History of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease
  5. Received a nutrient stimulating hormone (NuSH)-based therapy (eg, Glucagon-like peptide-1 receptor agonist [GLP-1RA]) within 6 months of the screening visit
  6. Planned initiation of NuSH-based therapy, bariatric surgery, or alternative procedures aimed at reducing weight or altering of body composition during the duration of the trial
  7. Received an anti-obesity medication within 90 days of screening visit

Note: Other protocol defined Inclusion/ Exclusion Criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
304 participants (estimated)

Study arms

  • Experimental
    Part A

    Drug: REGN20566 · Drug: Placebo

  • Placebo comparator
    Part B

    Drug: REGN20566 · Drug: Placebo

Interventions

  • DrugREGN20566

    Administered per the protocol

  • DrugPlacebo

    Administered per the protocol

07

What researchers measure

Primary outcomes

  1. Occurrence of Treatment Emergent Adverse Events (TEAEs)

    Part A

    Time frame: Up to 16 weeks

  2. Severity of TEAEs

    Part A

    Time frame: Up to 16 weeks

  3. Occurrence of TEAEs

    Part B

    Time frame: Up to 27 weeks

  4. Severity of TEAEs

    Part B

    Time frame: Up to 27 weeks

Secondary outcomes

  1. Concentration of REGN20566 in serum

    Part A

    Time frame: Baseline through week 16

  2. Concentration of REGN20566 in serum

    Part B

    Time frame: Baseline through week 27

  3. Occurrence of Anti-Drug Antibodies (ADA) to REGN20566

    Part A

    Time frame: Baseline through week 16

  4. Magnitude of ADA to REGN20566

    Part A

    Time frame: Baseline through week 16

  5. Occurrence of ADA to REGN20566

    Part B

    Time frame: Baseline through week 27

  6. Magnitude of ADA to REGN20566

    Part B

    Time frame: Baseline through week 27

08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Feb 2028, 13 months later.

Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 13 months is above that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartEst.
Dec 14, 2026
Primary completionEst.
Feb 2, 2028
CompletionEst.
Feb 2, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07947966
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Dec 14, 2026 (estimated)
Primary completion
Feb 2, 2028 (estimated)
Completion
Feb 2, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion